文献速递新生儿儿童感染

平衡液与生理盐水对PICU患儿血氯影响的随机临床试验

Effect of Saline vs Gluconate/Acetate-Buffered Solution vs Lactate-Buffered Solution on Serum Chloride Among Children in the Pediatric Intensive Care Unit: The SPLYT-P Randomized Clinical Trial.
PubMed 文献 · JAMA Pediatr · 2023-01-01

SPLYT-P单中心三臂开放标签随机试验纳入516例PICU患儿,比较葡糖酸盐/醋酸盐缓冲液、乳酸盐缓冲液与生理盐水对48小时内血氯升高≥5 mEq/L的影响。两种平衡液均使血氯升高的 odds 减半(OR 0.50 和 0.47),新发急性肾损伤在葡糖酸盐/醋酸盐组为6.1%、乳酸盐组3.7%、生理盐水组3.2%。

要点

  • 平衡液较生理盐水减少PICU患儿48小时内血氯升高≥5 mEq/L。
  • 葡糖酸盐/醋酸盐缓冲液OR 0.50(95%CI 0.31-0.83),乳酸盐缓冲液OR 0.47(95%CI 0.28-0.79)。
  • 新发急性肾损伤三组分别为6.1%、3.7%、3.2%。

核心结论

  • 在PICU患儿中,葡糖酸盐/醋酸盐缓冲液和乳酸盐缓冲液作为静脉液体治疗较生理盐水降低了血浆氯升高的发生率。

主要发现

  • 48小时内血清氯升高≥5 mEq/L的患者在葡糖酸盐/醋酸盐缓冲液组为37例(25.2%),乳酸盐缓冲液组为34例(23.9%),生理盐水组为58例(40.0%)。
  • 新发急性肾损伤在葡糖酸盐/醋酸盐缓冲液组为10例(6.1%),乳酸盐缓冲液组为6例(3.7%),生理盐水组为5例(3.2%)。

关键数值与推荐

  • 主要结局为随机化后48小时内血清氯升高≥5 mEq/L。
  • 次要结局包括新发急性肾损伤、住院和ICU停留时间、无ICU生存。

临床怎么用

  • 对于PICU中需要静脉液体治疗的危重患儿,可考虑使用葡糖酸盐/醋酸盐缓冲液或乳酸盐缓冲液以减少血氯升高。
  • 选择液体时需结合患儿具体情况,并关注新发急性肾损伤等次要结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Most children admitted to pediatric intensive care units (PICUs) receive intravenous fluids. A recent systematic review suggested mortality benefit in critically ill adults treated with balanced solutions compared with sodium chloride, 0.9% (saline). There is a lack of clinically directive data on optimal fluid choice in critically ill children. OBJECTIVE: To determine if balanced solutions decrease the rise of plasma chloride compared with saline, 0.9%, in critically ill children. DESIGN, SETTING, AND PARTICIPANTS: This single-center, 3-arm, open-label randomized clinical trial took place in a 36-bed PICU. Children younger than 16 years admitted to the PICU and considered to require intravenous fluid therapy by the treating clinician were eligible. Children were screened from November 2019 to April 2021. INTERVENTIONS: Enrolled children were 1:1:1 allocated to gluconate/acetate-buffered solution, lactate-buffered solution, or saline as intravenous fluids. MAIN OUTCOMES AND MEASURES: The primary outcome was an increase in serum chloride of 5 mEq/L or more within 48 hours from randomization. New-onset acute kidney injury, length of hospital and intensive care stay, and intensive care-free survival were secondary outcomes. RESULTS: A total of 516 patients with a median (IQR) age of 3.8 (1.0-10.4) years were randomized with 178, 171, and 167 allocated to gluconate/acetate-buffered solution, lactate-buffered solution, and saline, respectively. The serum chloride level increased 5 mEq/L or more in 37 patients (25.2%), 34 patients (23.9%), and 58 patients (40.0%) in the gluconate/acetate-buffered solution, lactate-buffered solution, and saline groups. The odds of a rise in plasma chloride 5 mEq/L or more was halved with the use of gluconate/acetate-buffered solution compared with saline (odds ratio, 0.50 [95% CI, 0.31-0.83]; P = .007) and with the use of lactate-buffered solution compared with saline (odds ratio, 0.47 [95% CI, 0.28-0.79]; P = .004). New-onset acute kidney injury was observed in 10 patients (6.1%), 6 patients (3.7%), and 5 patients (3.2%) in the gluconate/acetate-buffered solution, lactate-buffered solution, and saline groups, respectively. CONCLUSIONS AND RELEVANCE: Balanced solutions (gluconate/acetate-buffered solution and lactate-buffered solution) administered as intravenous fluid therapy reduced the incidence of rise in plasma chloride compared with saline in children in PICU. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12619001244190.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Raman S, Gibbons KS, Mattke A, et al. Effect of Saline vs Gluconate/Acetate-Buffered Solution vs Lactate-Buffered Solution on Serum Chloride Among Children in the Pediatric Intensive Care Unit: The SPLYT-P Randomized Clinical Trial. JAMA Pediatr. 2023. PMID: 36534387. doi:10.1001/jamapediatrics.2022.4912

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。